Comparative Pharmacology
Head-to-head clinical analysis: ATRIDOX versus DOXY 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRIDOX versus DOXY 100.
ATRIDOX vs DOXY 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATRIDOX (doxycycline hyclate) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases (MMPs) and reducing cytokine production.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
50 mg subgingival controlled-release insert applied by dental professional into periodontal pockets once every 3 months.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
None Documented
None Documented
Terminal half-life 16-18 hours; prolonged to 24-48 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
Primarily renal (60-70% unchanged), biliary/fecal (10-15%) as active drug and metabolites; remainder metabolized.
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic